{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-017908","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.514367+00:00","generated_at":"2026-06-13T20:01:12.592291+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AstraZeneca discontinues Phase 2a trial of elarekibep; lung findings from toxicology study","bullets":["AstraZeneca ceases dosing in clinical studies of elarekibep (IL-4Rα inhibitor for asthma) due to lung pathology from a 13-week GLP toxicology study.","Findings include inflammation-mediated lung tissue damage, not dose-related; no clinical observations in study.","Pieris to expedite review of program implications and reassess corporate priorities before further update.","Cash balance of $53.2 million as of May 31, 2023 (unaudited).","Decision independent of Phase 2a data; findings do not support long-term use or later-stage development."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-017908","json":"https://secwatch.observer/filing/0001437749-23-017908.json","markdown":"https://secwatch.observer/filing/0001437749-23-017908.md","text":"https://secwatch.observer/filing/0001437749-23-017908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923017908/0001437749-23-017908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923017908/pirs20230618_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:01:12.592291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}